Does the media prefer LFCR or DRUG?

In the previous week, Bright Minds Biosciences had 3 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.21 beat Bright Minds Biosciences' score of -0.92 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media favor LFCR or CTNM?

In the previous week, Contineum Therapeutics had 20 more articles in the media than Lifecore Biomedical. MarketBeat recorded 21 mentions for Contineum Therapeutics and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.21 beat Contineum Therapeutics' score of -0.17 indicating that Lifecore Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 9 Negative mention(s) 2 Very Negative mention(s) Neutral

Is EOLS or LFCR more profitable?

Evolus has a net margin of -10.85% compared to Lifecore Biomedical's net margin of -29.93%. Company Net Margins Return on Equity Return on Assets Evolus -10.85% N/A -13.00% Lifecore Biomedical -29.93% N/A -16.16%

Does the media favor EOLS or LFCR?

In the previous week, Evolus and Evolus both had 1 articles in the media. Evolus' average media sentiment score of 1.53 beat Lifecore Biomedical's score of 0.21 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LFCR or TLRY?

In the previous week, Tilray Brands had 16 more articles in the media than Lifecore Biomedical. MarketBeat recorded 17 mentions for Tilray Brands and 1 mentions for Lifecore Biomedical. Tilray Brands' average media sentiment score of 0.48 beat Lifecore Biomedical's score of 0.21 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tilray Brands 5 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Lifecore Biomedical (LFCR) Competitors

$4.46 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.46 0.00 (-0.11%)

As of 09/18/2026 07:30 PM Eastern

Compare

LFCR vs. DRUG, CRMD, CTNM, EOLS, and TLRY

Should you buy Lifecore Biomedical stock or one of its competitors? Lifecore Biomedical's main competitors and comparable companies include Bright Minds Biosciences (DRUG), CorMedix (CRMD), Contineum Therapeutics (CTNM), Evolus (EOLS), and Tilray Brands (TLRY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lifecore Biomedical compare to Bright Minds Biosciences?

Lifecore Biomedical (NASDAQ:LFCR) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Lifecore Biomedical currently has a consensus price target of $6.50, suggesting a potential upside of 45.74%. Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 135.87%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lifecore Biomedical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, suggesting that its share price is 636% less volatile than the broader market.

Bright Minds Biosciences has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

In the previous week, Bright Minds Biosciences had 3 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.21 beat Bright Minds Biosciences' score of -0.92 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Bright Minds Biosciences has lower revenue, but higher earnings than Lifecore Biomedical. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.31	-$40.50M	-$1.07	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Summary

Bright Minds Biosciences beats Lifecore Biomedical on 8 of the 15 factors compared between the two stocks.

How does Lifecore Biomedical compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

CorMedix has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.93	$163.05M	$2.14	3.61
Lifecore Biomedical	$128.87M	1.31	-$40.50M	-$1.07	N/A

CorMedix currently has a consensus target price of $15.00, suggesting a potential upside of 94.30%. Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 45.74%. Given CorMedix's stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

34.2% of CorMedix shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lifecore Biomedical had 1 more articles in the media than CorMedix. MarketBeat recorded 1 mentions for Lifecore Biomedical and 0 mentions for CorMedix. Lifecore Biomedical's average media sentiment score of 0.21 beat CorMedix's score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Neutral
Lifecore Biomedical	Neutral

CorMedix has a net margin of 40.49% compared to Lifecore Biomedical's net margin of -29.93%. CorMedix's return on equity of 40.52% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Lifecore Biomedical	-29.93%	N/A	-16.16%

CorMedix has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Summary

CorMedix beats Lifecore Biomedical on 12 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Contineum Therapeutics?

Lifecore Biomedical (NASDAQ:LFCR) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Lifecore Biomedical presently has a consensus target price of $6.50, suggesting a potential upside of 45.74%. Contineum Therapeutics has a consensus target price of $20.80, suggesting a potential upside of 53.73%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Contineum Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market.

In the previous week, Contineum Therapeutics had 20 more articles in the media than Lifecore Biomedical. MarketBeat recorded 21 mentions for Contineum Therapeutics and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.21 beat Contineum Therapeutics' score of -0.17 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	9 Negative mention(s)	2 Very Negative mention(s)	Neutral

83.4% of Lifecore Biomedical shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lifecore Biomedical has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.31	-$40.50M	-$1.07	N/A
Contineum Therapeutics	$50M	10.18	-$59.98M	-$1.73	N/A

Contineum Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Contineum Therapeutics	N/A	-24.73%	-23.51%

Summary

Lifecore Biomedical beats Contineum Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Evolus?

Evolus (NASDAQ:EOLS) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Evolus currently has a consensus price target of $14.50, suggesting a potential upside of 84.48%. Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 45.74%. Given Evolus' stronger consensus rating and higher possible upside, analysts plainly believe Evolus is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Evolus and Evolus both had 1 articles in the media. Evolus' average media sentiment score of 1.53 beat Lifecore Biomedical's score of 0.21 indicating that Evolus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lifecore Biomedical has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.75	-$51.64M	-$0.52	N/A
Lifecore Biomedical	$128.87M	1.31	-$40.50M	-$1.07	N/A

Evolus has a net margin of -10.85% compared to Lifecore Biomedical's net margin of -29.93%.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-10.85%	N/A	-13.00%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Evolus has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

90.7% of Evolus shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Evolus beats Lifecore Biomedical on 11 of the 14 factors compared between the two stocks.

How does Lifecore Biomedical compare to Tilray Brands?

Lifecore Biomedical (NASDAQ:LFCR) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

In the previous week, Tilray Brands had 16 more articles in the media than Lifecore Biomedical. MarketBeat recorded 17 mentions for Tilray Brands and 1 mentions for Lifecore Biomedical. Tilray Brands' average media sentiment score of 0.48 beat Lifecore Biomedical's score of 0.21 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tilray Brands	5 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 0.8% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tilray Brands has a net margin of -13.11% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Tilray Brands	-13.11%	-7.76%	-5.59%

Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Lifecore Biomedical has higher earnings, but lower revenue than Tilray Brands. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.31	-$40.50M	-$1.07	N/A
Tilray Brands	$915.45M	0.59	-$121.40M	-$1.08	N/A

Lifecore Biomedical currently has a consensus price target of $6.50, indicating a potential upside of 45.74%. Tilray Brands has a consensus price target of $8.00, indicating a potential upside of 100.50%. Given Tilray Brands' stronger consensus rating and higher possible upside, analysts clearly believe Tilray Brands is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Summary

Tilray Brands beats Lifecore Biomedical on 11 of the 17 factors compared between the two stocks.

Get Lifecore Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFCR vs. The Competition

Export

Metric	Lifecore Biomedical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$168.82M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-4.17	792.21	274.93	25.38
Price / Sales	1.31	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	10.62	10.53	10.46	6.33
Net Income	-$40.50M	$2.82B	$3.49B	$358.33M
7 Day Performance	8.25%	1.69%	0.59%	1.12%
1 Month Performance	N/A	0.83%	-2.01%	-2.67%
1 Year Performance	-43.33%	3.90%	18.09%	6.01%

Lifecore Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFCR Lifecore Biomedical	1.3295 of 5 stars	$4.46 flat	$6.50 +45.7%	-43.8%	$168.82M	$128.87M	N/A	382	Positive News High Trading Volume
DRUG Bright Minds Biosciences	2.3053 of 5 stars	$66.91 +2.7%	$143.83 +115.0%	+21.6%	$651.18M	N/A	N/A	N/A	News Coverage Analyst Downgrade
CRMD CorMedix	2.289 of 5 stars	$8.18 -3.0%	$15.00 +83.4%	-34.0%	$637.58M	$457.20M	3.82	30
CTNM Contineum Therapeutics	1.8024 of 5 stars	$15.94 -4.6%	$20.25 +27.0%	+9.1%	$628.27M	$50M	N/A	31	News Coverage Analyst Forecast Options Volume
EOLS Evolus	3.0692 of 5 stars	$8.88 -4.5%	$14.50 +63.3%	+22.4%	$614.27M	$297.18M	N/A	170	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFCR) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifecore Biomedical (LFCR) Competitors

LFCR vs. DRUG, CRMD, CTNM, EOLS, and TLRY

How does Lifecore Biomedical compare to Bright Minds Biosciences?

Summary

How does Lifecore Biomedical compare to CorMedix?

Summary

How does Lifecore Biomedical compare to Contineum Therapeutics?

Summary

How does Lifecore Biomedical compare to Evolus?

Summary

How does Lifecore Biomedical compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifecore Biomedical (LFCR) Competitors

LFCR vs. DRUG, CRMD, CTNM, EOLS, and TLRY

How does Lifecore Biomedical compare to Bright Minds Biosciences?

Do analysts prefer LFCR or DRUG?

Do insiders and institutionals have more ownership in LFCR or DRUG?

Which has more volatility and risk, LFCR or DRUG?

Is LFCR or DRUG more profitable?

Does the media prefer LFCR or DRUG?

Which has better valuation & earnings, LFCR or DRUG?

Summary

How does Lifecore Biomedical compare to CorMedix?

Which has better earnings and valuation, CRMD or LFCR?

Do analysts recommend CRMD or LFCR?

Do insiders & institutionals hold more shares of CRMD or LFCR?

Does the media prefer CRMD or LFCR?

Is CRMD or LFCR more profitable?

Which has more volatility and risk, CRMD or LFCR?

Summary

How does Lifecore Biomedical compare to Contineum Therapeutics?

Do analysts rate LFCR or CTNM?

Which has more risk and volatility, LFCR or CTNM?

Does the media favor LFCR or CTNM?

Do insiders and institutionals have more ownership in LFCR or CTNM?

Which has higher valuation and earnings, LFCR or CTNM?

Is LFCR or CTNM more profitable?

Summary

How does Lifecore Biomedical compare to Evolus?

Do analysts rate EOLS or LFCR?

Does the media favor EOLS or LFCR?

Which has preferable earnings & valuation, EOLS or LFCR?

Is EOLS or LFCR more profitable?

Which has more volatility and risk, EOLS or LFCR?

Do institutionals & insiders hold more shares of EOLS or LFCR?

Summary

How does Lifecore Biomedical compare to Tilray Brands?

Does the media favor LFCR or TLRY?

Do insiders and institutionals believe in LFCR or TLRY?

Is LFCR or TLRY more profitable?

Which has more volatility and risk, LFCR or TLRY?

Which has stronger valuation & earnings, LFCR or TLRY?

Do analysts prefer LFCR or TLRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools